NY-THE-LIVEKINDLY-CO.
11.3.2020 11:02:14 CET | Business Wire | Press release
The LIVEKINDLY co. is leading a movement to build a sustainable future, today, fueled by a $200-million founders’ funding round led by founders, entrepreneurs, and global leaders. Establishing a collective of heritage and start-up brands, the company is on track to become one of the world’s largest plant-based food companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200311005184/en/
Brands under the LIVEKINDLY co. portfolio offer consumers non-GMO, plant-based chicken alternatives and include: The Fry Family Food Co. and LikeMeat, as well as the fastest-growing plant-based digital media platform, LIVEKINDLY Media –from which the new company's name derives and means embracing a sustainable and compassionate lifestyle. With these investments and an equity stake in PURIS Holding , a vertically integrated player of non-GMO, plant-based ingredients, the LIVEKINDLY co. is the only company in the plant-based food sector to own and operate the entire value chain of production.
The LIVEKINDLY co. is committed to transforming the global food system by partnering with forward-looking poultry production companies seeking to embrace and contribute to plant-based options. Products offer consumers recognizable natural ingredients made with environmentally friendly meat alternatives that mimic the taste and texture of chicken.
Plant-based food products are becoming increasingly popular as consumer demand for cleaner, more sustainable options grow, and production technologies improve to significantly enhance taste and texture. The plant-based protein market could reach 9% of the estimated $2.7 trillion global meat market by 20401 , positioning the LIVEKINDLY co. for strong future growth.
Leading the LIVEKINDLY co. is a global team of industry executives including Kees Kruythoff, Chairman & CEO (formerly President Unilever North America and Global Home Care Division); Roger Lienhard, Board of Directors and Founder (founder of Blue Horizon Corporation); and Jodi Monelle , CEO and Founder LIVEKINDLY Media. The leadership team includes veterans of the food industry: Mick Van Ettinger , Chief Marketing Officer (formerly of Unilever), and Aldo Uva , COO and Chief R&D Officer (formerly of Nestle, Firmenich, and Ferrero).
“Unlike any other company in this space, the LIVEKINDLY co. is creating a movement that will drive impact at scale and at speed,” said Kruythoff. “We are starting with one of the world’s most consumed meats–chicken-by providing outstanding, tasty, plant-based foods that are more sustainable and environmentally friendly. We’re also partnering with incumbent poultry companies including PHW in Europe and RCL Foods in South Africa, who are committed to embracing plant-based options.”
“The LIVEKINDLY co.'s approach offers a path forward for transforming the global food industry. Our team has built a new formula for success by bringing innovation, experience, resources, and scale throughout the plant-based chicken value chain,” said Lienhard. “It started with bringing together like-minded founders who share a vision for smarter, sustainable living, and allows the food industry to better align around the evolving values of consumers who are focused on climate change, animal welfare, and human health.”
The founders’ round of funding will be used for further acquisitions, scaling the current plant-based food portfolio of brands and investments to rapidly increase the plant-based food industry capacity.
ABOUT THE LIVEKINDLY CO.
The LIVEKINDLY co. is a collective of plant-based heritage and start-up brands including: The Fry Family Food Co., LikeMeat, and LIVEKINDLY Media.
Committed to transforming our global food system and the only company in the plant-based food sector to own and operate the entire value chain of production, the LIVEKINDLY co. has established strategic partnerships with seed growers, producers, distributors, and has invested in infrastructure to transform traditional meat production facilities to plant-based products.
The LIVEKINDLY co. and its portfolio of brands are creating delicious plant-based food without the need for animals or the depletion of natural resources. We’re bringing kindness where it belongs: to your plate.
ABOUT BLUE HORIZON CORPORATION
Blue Horizon was founded in 2015 with the vision that profit-oriented strategies and the common good can be united. Blue Horizon is a global-mission-driven private sector investment firm focused on scalable ventures that accelerate that global transition towards sustainable food and agriculture.
To learn more, visit our website .
1 https://www.jefferies.com/CMSFiles/Jefferies.com/Files/Insights/The_Great_Protein_Shakeup.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005184/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
